Qurient Co., Ltd. (KOSDAQ:115180)

South Korea · Delayed Price · Currency is KRW

22,500

-450 (-1.96%)

At close: Sep 9, 2026

Market Cap	914.95B +91.1%
Revenue (ttm)	7.07B -20.1%
Net Income	-38.44B
EPS	-1,056.94
Shares Out	40.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,430
Open	22,500
Previous Close	22,950
Day's Range	21,550 - 23,000
52-Week Range	10,980 - 62,900
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2008

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 115180

Full Company Profile

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.12 billion, 24.9% more than in 2024.

Financial Statements